General Trading Chat

Where would you enter in the above scenario? :)
Yesterday 36.25 was a strong support. The longs could keep that area as the SL. Haven't traded it so far today. Poor range.
 
If I consider the 2 bands as the range, I get lower value at 36.5 and upper band at 38.7 when measured at market open (1st candle). Normal std. deviation can be calculated as (38.7 - 36.5)/sqrt(2)... this gives 1.55.
Now since we are shorting, I would deduct this from top band and arrive at the potential entry point of 37.15 with stop at 38.7
This is the way I would approach this stock. :)
 
Not a day to short this, I think. The supertrend has been bullish today. The ADX has been rising (it has crossed 40 but doesn't indicate end of today's trend).

1581580784876.png


Not a day to short, IMO. I think that with a small ticket ticker like this, 1.5Rs. is a huge SL.
 
https://timesofindia.indiatimes.com/biz-drreddys-wockhardt/articleshow/74096301.cms

PTI | Feb 12, 2020, 01.22 PM IST

Dr Reddy's to acquire Wockhardts select generics for Rs 1850cr

Hyderabad, Feb 12 () Dr Reddy's Laboratories Ltd entered into a definitive agreement with Wockhardt Ltd to acquire select divisions of its branded generics business in India and a few other international territories, includingSri Lanka and Maldives for Rs 1850 crores, the drug maker said on Wednesday. The business comprises of a portfolio of 62 brands in multiple therapy areas such as Respiratory, Neurology, VMS,Dermatology, Pain and Vaccines, which would transfer to DrReddy's along with related sales and marketing teams and the manufacturing plant located in Baddi, Himachal Pradesh with all plant employees, a release said. The business undertaking is being transferred on an outright sale basis.

The Co-Chairman and Managing Director of Dr Reddy's, G VPrasad said, "India is an important market for us and this acquisition will help in considerably scaling-up our domestic business."

"The acquired portfolio shall enhance Dr Reddy's presence in the high growth therapy areas with market leading brands such as Practin, Zedex, Bro-zedex, Tryptomer and Biovac.

We believe the portfolio holds a lot of potential and will get an impetus under Dr Reddy's. We welcome the team joining as part of the deal to the Dr Reddy's family." The transaction is expected to be closed in the first quarter of the financial year 2020-21.
 
?? Bad news for PSU banks ??

RBI new asset recognition norms credit negative for banks: Moody's
1 min read . Updated: 13 Feb 2020, 06:45 PM ISTPTI
  • It said the revisions of the date of DCCO and consequential shift in repayment schedule for equal or shorter duration will not be treated as restructuring provided the revised DCCO falls
  • Developers are facing funding challenges because non-bank financial institutions the key lenders to the sector
https://www.livemint.com/industry/b...egative-for-banks-moody-s-11581599550486.html
 

siddhant4u

Well-Unknown Member

Similar threads

Broker Special Offers

Intraday Higher Leverage

Save up to 90% in brokerage and get higher leverage for intraday trades.

Name:Phone:
Email:City:
State:
Are you a day trader?